{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35013112", "DateCompleted": {"Year": "2022", "Month": "03", "Day": "25"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "17"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "01", "Day": "10"}], "Language": ["eng"], "ELocationID": ["45", "10.1038/s41419-021-04495-w"], "Journal": {"ISSN": "2041-4889", "JournalIssue": {"Volume": "13", "Issue": "1", "PubDate": {"Year": "2022", "Month": "Jan", "Day": "10"}}, "Title": "Cell death & disease", "ISOAbbreviation": "Cell Death Dis"}, "ArticleTitle": "PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer.", "Pagination": {"StartPage": "45", "MedlinePgn": "45"}, "Abstract": {"AbstractText": ["PHY34 is a synthetic small molecule, inspired by a compound naturally occurring in tropical plants of the Phyllanthus genus. PHY34 was developed to have potent in vitro and in vivo anticancer activity against high grade serous ovarian cancer (HGSOC) cells. Mechanistically, PHY34 induced apoptosis in ovarian cancer cells by late-stage autophagy inhibition. Furthermore, PHY34 significantly reduced tumor burden in a xenograft model of ovarian cancer. In order to identify its molecular target/s, we undertook an unbiased approach utilizing mass spectrometry-based chemoproteomics. Protein targets from the nucleocytoplasmic transport pathway were identified from the pulldown assay with the cellular apoptosis susceptibility (CAS) protein, also known as CSE1L, representing a likely candidate protein. A tumor microarray confirmed data from mRNA expression data in public databases that CAS expression was elevated in HGSOC and correlated with worse clinical outcomes. Overexpression of CAS reduced PHY34 induced apoptosis in ovarian cancer cells based on PARP cleavage and Annexin V staining. Compounds with a diphyllin structure similar to PHY34 have been shown to inhibit the ATP6V0A2 subunit of V(vacuolar)-ATPase. Therefore, ATP6V0A2 wild-type and ATP6V0A2 V823 mutant cell lines were tested with PHY34, and it was able to induce cell death in the wild-type at 246\u2009pM while the mutant cells were resistant up to 55.46\u2009nM. Overall, our data demonstrate that PHY34 is a promising small molecule for cancer therapy that targets the ATP6V0A2 subunit to induce autophagy inhibition while interacting with CAS and altering nuclear localization of proteins."], "CopyrightInformation": "\u00a9 2022. The Author(s)."}, "AuthorList": [{"Identifier": ["0000-0003-0946-5923"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Salvi", "ForeName": "Amrita", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Young", "ForeName": "Alexandria N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA."}], "LastName": "Huntsman", "ForeName": "Andrew C", "Initials": "AC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Pergande", "ForeName": "Melissa R", "Initials": "MR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Korkmaz", "ForeName": "Melissa A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Rathnayake", "ForeName": "Rathnayake A", "Initials": "RA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA."}], "LastName": "Mize", "ForeName": "Brittney K", "Initials": "BK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA."}], "LastName": "Kinghorn", "ForeName": "A Douglas", "Initials": "AD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Informatics, The Ohio State University, Columbus, OH, 43210, USA."}], "LastName": "Zhang", "ForeName": "Xiaoli", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Ratia", "ForeName": "Kiira", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA."}], "LastName": "Schirle", "ForeName": "Markus", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA."}], "LastName": "Thomas", "ForeName": "Jason R", "Initials": "JR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA."}], "LastName": "Brittain", "ForeName": "Scott M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA."}], "LastName": "Shelton", "ForeName": "Claude", "Initials": "C"}, {"Identifier": ["0000-0001-8406-720X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Aldrich", "ForeName": "Leslie N", "Initials": "LN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA."}], "LastName": "Cologna", "ForeName": "Stephanie M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA."}], "LastName": "Fuchs", "ForeName": "James R", "Initials": "JR"}, {"Identifier": ["0000-0002-7271-6847"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60607, USA. joannab@uic.edu."}], "LastName": "Burdette", "ForeName": "Joanna E", "Initials": "JE"}], "GrantList": [{"GrantID": "F30 CA217079", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "P01 CA125066", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "P01CA125066", "Agency": "U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)", "Country": ""}, {"GrantID": "1F30CA217079", "Agency": "U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)", "Country": ""}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Cell Death Dis", "NlmUniqueID": "101524092"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "ATP6V0A2 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Cellular Apoptosis Susceptibility Protein"}, {"RegistryNumber": "EC 3.6.3.14", "NameOfSubstance": "Proton-Translocating ATPases"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Active Transport, Cell Nucleus"}, {"QualifierName": ["metabolism", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Autophagy"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cell Nucleus"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Cellular Apoptosis Susceptibility Protein"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Cystadenocarcinoma, Serous"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Ovarian Neoplasms"}, {"QualifierName": ["chemistry"], "DescriptorName": "Phyllanthus"}, {"QualifierName": [], "DescriptorName": "Prognosis"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Proton-Translocating ATPases"}], "CoiStatement": "MS, JRT, SMB, CS are employees of Novartis Institutes for BioMedical Research. The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria P-J, Bast RC, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.", "ArticleIdList": ["PMC4892184", "26493647"]}, {"Citation": "Moore KN, Pothuri B, Monk B, Coleman RL. PARP inhibition as frontline therapy in ovarian cancer. Clin Adv Hematol Oncol. 2020;18:550\u20136.", "ArticleIdList": ["33006584"]}, {"Citation": "Ledermann JA. Extending the scope of PARP inhibitors in ovarian cancer. Lancet Oncol. 2019;20:470\u20132.", "ArticleIdList": ["30880068"]}, {"Citation": "Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403\u201315.", "ArticleIdList": ["PMC6941439", "31562800"]}, {"Citation": "Whitton B, Okamoto H, Packham G, Crabb SJ. Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Med. 2018;7:3800\u201311.", "ArticleIdList": ["PMC6089187", "29926527"]}, {"Citation": "Kulshrestha A, Katara GK, Ginter J, Pamarthy S, Ibrahim SA, Jaiswal MK, et al. Selective inhibition of tumor cell associated Vacuolar-ATPase \u201ca2\u201d isoform overcomes cisplatin resistance in ovarian cancer cells. Mol Oncol. 2016;10:789\u2013805.", "ArticleIdList": ["PMC5423172", "26899534"]}, {"Citation": "Kulshrestha A, Katara GK, Ibrahim S, Pamarthy S, Jaiswal MK, Sachs AG, et al. Vacuolar ATPase \u201ca2\u201d isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. Oncotarget. 2015;6:3797\u2013810.", "ArticleIdList": ["PMC4414154", "25686833"]}, {"Citation": "Kulshrestha A, Katara GK, Ibrahim SA, Riehl V, Sahoo M, Dolan J, et al. Targeting V-ATPase isoform restores cisplatin activity in resistant ovarian cancer: inhibition of autophagy, endosome function, and ERK/MEK pathway. J Oncol. 2019;2019:e2343876.", "ArticleIdList": ["PMC6463777", "31057611"]}, {"Citation": "S\u00f8rensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Min Res. 2007;22:1640\u20138.", "ArticleIdList": ["17576165"]}, {"Citation": "Shen W, Zou X, Chen M, Liu P, Shen Y, Huang S, et al. Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma. Eur J Pharm. 2011;667:330\u20138.", "ArticleIdList": ["21645513"]}, {"Citation": "Chen H, Liu P, Zhang T, Gao Y, Zhang Y, Shen X, et al. Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cells. Oncol Rep. 2018;39:921\u20138.", "ArticleIdList": ["PMC5802041", "29328465"]}, {"Citation": "Wang AC, Pham HT, Lipps JM, Brittain SM, Harrington E, Wang Y, et al. Previously uncharacterized vacuolar-type ATPase binding site discovered from structurally similar compounds with distinct mechanisms of action. ACS Chem Biol. 2019;14:20\u20136.", "ArticleIdList": ["30461263"]}, {"Citation": "Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14:1435\u201355.", "ArticleIdList": ["PMC6103682", "29940786"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(Mar):770\u2013803.", "ArticleIdList": ["32162523"]}, {"Citation": "Ren Y, Lantvit DD, Deng Y, Kanagasabai R, Gallucci JC, Ninh TN, et al. Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei. J Nat Prod. 2014;77:1494\u2013504.", "ArticleIdList": ["PMC4073661", "24937209"]}, {"Citation": "Woodard JL, Huntsman AC, Patel PA, Chai H-B, Kanagasabai R, Karmahapatra S, et al. Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones. Bioorg Med Chem. 2018;26:2354\u201364.", "ArticleIdList": ["PMC5962029", "29656990"]}, {"Citation": "Young AN, Herrera D, Huntsman AC, Korkmaz MA, Lantvit DD, Mazumder S, et al. Phyllanthusmin derivatives induce apoptosis and reduce tumor burden in high-grade serous ovarian cancer by late-stage autophagy inhibition. Mol Cancer Ther. 2018;17:2123\u201335.", "ArticleIdList": ["PMC6168422", "30018048"]}, {"Citation": "Delaney JR, Patel CB, Willis KM, Haghighiabyaneh M, Axelrod J, Tancioni I, et al. Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer. Nat Commun. 2017;8:14423.", "ArticleIdList": ["PMC5316854", "28198375"]}, {"Citation": "Kutay U, Bischoff FR, Kostka S, Kraft R, G\u00f6rlich D. Export of Importin \u03b1 from the nucleus is mediated by a specific nuclear transport factor. Cell. 1997;90:1061\u201371.", "ArticleIdList": ["9323134"]}, {"Citation": "Behrens P, Brinkmann U, Wellmann A. CSE1L/CAS: Its role in proliferation and apoptosis. Apoptosis. 2003;8:39\u201344.", "ArticleIdList": ["12510150"]}, {"Citation": "Dong Q, Li X, Wang C-Z, Xu S, Yuan G, Shao W, et al. Roles of the CSE1L-mediated nuclear import pathway in epigenetic silencing. PNAS. 2018;115:E4013\u201322.", "ArticleIdList": ["PMC5924926", "29636421"]}, {"Citation": "Liao C-F, Lin S-H, Chen H-C, Tai C-J, Chang C-C, Li L-T, et al. CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells. Mol Med. 2012;18:1269\u201380.", "ArticleIdList": ["PMC3521793", "22952058"]}, {"Citation": "Fu X, Liang C, Li F, Wang L, Wu X, Lu A, et al. The rules and functions of nucleocytoplasmic shuttling proteins. Int J Mol Sci. 2018;19:1445.", "ArticleIdList": ["PMC5983729", "29757215"]}, {"Citation": "Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779\u201384.", "ArticleIdList": ["PMC5709193", "29083409"]}, {"Citation": "Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer. 2007;46:1\u20139.", "ArticleIdList": ["17044060"]}, {"Citation": "Lorenzato A, Biolatti M, Delogu G, Capobianco G, Farace C, Dessole S, et al. AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells. Exp Cell Res. 2013;319(Oct):2627\u201336.", "ArticleIdList": ["23948303"]}, {"Citation": "Alnabulsi A, Agouni A, Mitra S, Garcia\u2010Murillas I, Carpenter B, Bird S, et al. Cellular apoptosis susceptibility (chromosome segregation 1-like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. J Pathol. 2012;228:471\u201381.", "ArticleIdList": ["22450763"]}, {"Citation": "Liu C, Wei J, Xu K, Sun X, Zhang H, Xiong C. CSE1L participates in regulating cell mitosis in human seminoma. Cell Prolif. 2019;52:e12549.", "ArticleIdList": ["PMC6496685", "30485574"]}, {"Citation": "Behrens P, Brinkmann U, Fogt F, Wernert N, Wellmann A. Implication of the proliferation and apoptosis associated CSE1L/CAS gene for breast cancer development. Anticancer Res. 2001;21:2413\u20137.", "ArticleIdList": ["11724300"]}, {"Citation": "Shiraki K, Fujikawa K, Sugimoto K, Ito T, Yamanaka T, Suzuki M, et al. Cellular apoptosis susceptibility protein and proliferation in human hepatocellular carcinoma. Int J Mol Med. 2006;18:77\u201381.", "ArticleIdList": ["16786158"]}, {"Citation": "Wellmann A, Flemming P, Behrens P, Wuppermann K, Lang H, Oldhafer K, et al. High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. Int J Mol Med. 2001;7:489\u201394.", "ArticleIdList": ["11295109"]}, {"Citation": "Papay J, Krenacs T, Moldvay J, Stelkovics E, Furak J, Molnar B, et al. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach. Appl Immunohistochem Mol Morphol. 2007;15:19\u201330.", "ArticleIdList": ["17536303"]}, {"Citation": "Chang C-C, Tai C-J, Su T-C, Shen K-H, Lin S-H, Yeh C-M, et al. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas. Ann Diagnostic Pathol. 2012;16(Oct):362\u20138.", "ArticleIdList": ["22476051"]}, {"Citation": "Li KK-W, Yang L, Pang JC-S, Chan AK-Y, Zhou L, Mao Y, et al. MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L. Brain Pathol. 2013;23:426\u201339.", "ArticleIdList": ["PMC8028883", "23252729"]}, {"Citation": "Holzer K, Drucker E, Oliver S, Winkler J, Eiteneuer E, Herpel E, et al. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: a potential link to the BRAFV600E mutation. Int J Oncol. 2016;48:1679\u201387.", "ArticleIdList": ["26892809"]}, {"Citation": "Jiang K, Neill K, Cowden D, Klapman J, Eschrich S, Pimiento J, et al. Expression of CAS/CSE1L, the cellular apoptosis susceptibility protein, correlates with neoplastic progression in Barrett\u2019s esophagus. Appl Immunohistochem Mol Morphol. 2018;26:552\u20136.", "ArticleIdList": ["PMC5466515", "27941559"]}, {"Citation": "Soldini D, Montagna C, Sch\u00fcffler P, Martin V, Georgis A, Thiesler T, et al. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol. 2013;24(Jan):193\u2013201.", "ArticleIdList": ["22967991"]}, {"Citation": "Vaidyanathan S, Thangavelu PU, Duijf PHG. Overexpression of ran GTPase components regulating nuclear export, but not mitotic spindle assembly, marks chromosome instability and poor prognosis in breast cancer. Targ Oncol. 2016;11:677\u201386.", "ArticleIdList": ["27023921"]}, {"Citation": "Lorenzato A, Martino C, Dani N, Oligschl\u00e4ger Y, Ferrero AM, Biglia N, et al. The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB J. 2012;26:2446\u201356.", "ArticleIdList": ["22389439"]}, {"Citation": "Zhu J-H, Hong D-F, Song Y-M, Sun L-F, Wang Z-F, Wang J-W. Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells. Asian Pac J Cancer Prev. 2013;14:1017\u201321.", "ArticleIdList": ["23621178"]}, {"Citation": "Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72:3499\u2013511.", "ArticleIdList": ["PMC3399763", "22802077"]}, {"Citation": "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1\u2013pl1.", "ArticleIdList": ["PMC4160307", "23550210"]}, {"Citation": "Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disco. 2012;2:401\u20134.", "ArticleIdList": ["PMC3956037", "22588877"]}, {"Citation": "Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166\u201380.", "ArticleIdList": ["PMC1813932", "17356713"]}, {"Citation": "Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043\u20138.", "ArticleIdList": ["16921376"]}, {"Citation": "Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J. et al. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. Clin Cancer Res. 2019;26:54\u201360.", "ArticleIdList": ["PMC7787346", "31636097"]}, {"Citation": "Stelma T, Chi A, Watt PJ, van der, Verrico A, Lavia P, Leaner VD. Targeting nuclear transporters in cancer: diagnostic, prognostic and therapeutic potential. IUBMB Life. 2016;68:268\u201380.", "ArticleIdList": ["26970212"]}, {"Citation": "Lin F, Gao L, Su Z, Cao X, Zhan Y, Li Y, et al. Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation. Oncol Rep. 2018;40:179\u201394.", "ArticleIdList": ["PMC6059741", "29781035"]}, {"Citation": "Li Z, Hao P, Li L, Tan CYJ, Cheng X, Chen GYJ, et al. Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling. Angew Chem Int Ed Engl. 2013;52:8551\u20136.", "ArticleIdList": ["23754342"]}, {"Citation": "Lorkowski SW, Brubaker G, Gulshan K, Smith JD. V-ATPase (Vacuolar ATPase) activity required for ABCA1 (ATP-binding cassette protein A1)-mediated cholesterol efflux. Arterioscler Thromb Vasc Biol. 2018;38:2615\u201325.", "ArticleIdList": ["PMC6209108", "30354238"]}, {"Citation": "Chin S-Y, Wu P-R, Shih Y-H, Yeh C-M, Lee W-R, Shen S-C, et al. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi. Int J Clin Exp Pathol. 2015;8:1393\u2013401.", "ArticleIdList": ["PMC4396273", "25973023"]}, {"Citation": "Jans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. Curr Opin Cell Biol. 2019;58:50\u201360.", "ArticleIdList": ["30826604"]}, {"Citation": "Chen H-W, Cheng JX, Liu M-T, King K, Peng J-Y, Zhang X-Q, et al. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antivir Res. 2013;99:371\u201382.", "ArticleIdList": ["PMC3787953", "23820269"]}, {"Citation": "Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, et al. KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Br J Cancer. 2015;112:1929\u201337.", "ArticleIdList": ["PMC4580386", "25989275"]}, {"Citation": "Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.", "ArticleIdList": ["PMC3163504", "21720365"]}, {"Citation": "Patil R, Kulshrestha A, Tikoo A, Fleetwood S, Katara G, Kolli B, et al. Identification of novel bisbenzimidazole derivatives as anticancer vacuolar (H+)-ATPase inhibitors. Molecules. 2017;22:1559.", "ArticleIdList": ["PMC6151825", "28926955"]}, {"Citation": "Aldrich LN, Kuo S-Y, Castoreno AB, Goel G, Kuballa P, Rees MG, et al. Discovery of a small-molecule probe for V-ATPase function. J Am Chem Soc. 2015;137:5563\u20138.", "ArticleIdList": ["PMC4416280", "25860544"]}, {"Citation": "Vakifahmetoglu-Norberg H, Xia H, Yuan J. Pharmacologic agents targeting autophagy. J Clin Invest. 2015;125:5\u201313.", "ArticleIdList": ["PMC4382252", "25654545"]}, {"Citation": "Werner G, Hagenmaier H, Drautz H, Baumgartner A, Z\u00e4hner H. Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity. J Antibiot. 1984;37:110\u20137.", "ArticleIdList": ["6423597"]}, {"Citation": "Soderholm JF, Bird SL, Kalab P, Sampathkumar Y, Hasegawa K, Uehara-Bingen M, et al. Importazole, a small molecule inhibitor of the transport receptor importin-\u03b2. ACS Chem Biol. 2011;6:700\u20138.", "ArticleIdList": ["PMC3137676", "21469738"]}, {"Citation": "Suzuki T, Okamura T, Tomohiro T, Iwabuchi Y, Kanoh N. Third generation photo-cross-linked small-molecule affinity matrix: a photoactivatable and photocleavable system enabling quantitative analysis of the photo-cross-linked small molecules and their target purification. Bioconjug Chem. 2015;26:389\u201395.", "ArticleIdList": ["25668603"]}, {"Citation": "Britton S, Dernoncourt E, Delteil C, Froment C, Schiltz O, Salles B, et al. DNA damage triggers SAF-A and RNA biogenesis factors exclusion from chromatin coupled to R-loops removal. Nucleic Acids Res. 2014;42:9047\u201362.", "ArticleIdList": ["PMC4132723", "25030905"]}, {"Citation": "Hardy LR, Pergande MR, Esparza K, Heath KN, \u00d6ny\u00fcksel H, Cologna SM, et al. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton. Oncogene. 2019;38:6003\u201316 .", "ArticleIdList": ["PMC6687548", "31296958"]}, {"Citation": "Tobin MK, Stephen TKL, Lopez KL, Pergande MR, Bartholomew AM, Cologna SM, et al. Activated mesenchymal stem cells induce recovery following stroke via regulation of inflammation and oligodendrogenesis. J Am Heart Assoc. 2020;9:e013583.", "ArticleIdList": ["PMC7428606", "32204666"]}, {"Citation": "Studier FW. Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif. 2005;41:207\u201334.", "ArticleIdList": ["15915565"]}, {"Citation": "Salvi A, Amrine CSM, Austin JR, Kilpatrick K, Russo A, Lantvit D, et al. Verticillin A causes apoptosis and reduces tumor burden in high-grade serous ovarian cancer by inducing DNA damage. Mol Cancer Ther. 2020;19:89\u2013100.", "ArticleIdList": ["PMC6951445", "31909733"]}, {"Citation": "Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.", "ArticleIdList": ["PMC4053721", "24485249"]}, {"Citation": "Gordon A, Glazko G, Qiu X, Yakovlev A. Control of the mean number of false discoveries, Bonferroni and stability of multiple testing. Ann Appl Stat. 2007;1:179\u201390."}, {"Citation": "Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112\u20136.", "ArticleIdList": ["17406391"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "19"}, {"Year": "2021", "Month": "12", "Day": "17"}, {"Year": "2021", "Month": "11", "Day": "29"}, {"Year": "2022", "Month": "1", "Day": "11", "Hour": "6", "Minute": "27"}, {"Year": "2022", "Month": "1", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "10"}], "PublicationStatus": "epublish", "ArticleIdList": ["35013112", "PMC8748433", "10.1038/s41419-021-04495-w", "10.1038/s41419-021-04495-w"]}}], "PubmedBookArticle": []}